Patient characteristics of all eligible patients, and of patients assigned to chemotherapy or to allo-HSCT by ITT
| Characteristic . | Whole series (n = 348) . | Chemotherapy (n = 218) . | Allo-HSCT (n = 106) . |
|---|---|---|---|
| Age, y | |||
| Median, range | 40 (15-60) | 39 (15-60) | 39 (16-60) |
| ≥30 y (%) | 262 (75) | 163 (75) | 76 (72) |
| Sex (%) | |||
| Male | 212 (61) | 128 (59) | 71 (67) |
| Female | 136 (39) | 90 (41) | 35 (33) |
| Extramedullary involvement | |||
| Mediastinum (%) | 51/334 (15) | 35/208 (17) | 15/103 (15) |
| CNS (%) | 38/331 (11) | 19/211 (9)† | 16/99 (16)† |
| Testicle (%) | 2/194 (1) | 1/119 (1) | 1/63 (2) |
| Other (%) | 21/328 (6)* | 12/207 (6) | 6/98 (6) |
| WBC count, ×109/L | |||
| Median, range | 13.5 (0.2-638) | 14.7 (0.2-564) | 13.2 (0.6-638) |
| WBC >30 × 109/L (%) | 138 (40) | 85 (39) | 43 (41) |
| WBC >100 × 109/L (%) | 64 (18) | 37 (17) | 25 (24) |
| Immunophenotype (%) | |||
| BCP | 241 (69) | 147 (67) | 74 (70) |
| Early pre-B | 39 (11) | 15 (7) | 19 (18) |
| Common | 158 (46) | 99 (45) | 48 (45) |
| Pre-B | 43 (12) | 33 (15) | 7 (7) |
| B, nonspecified | 1 (0.5) | 0 | 0 |
| T-ALL | 107 (31) | 71 (33) | 32 (30) |
| Early pre-T | 23 (7) | 5 (2)‡ | 17 (16)‡ |
| Pre-T | 19 (5.5) | 15 (7) | 3 (3) |
| Cortical | 42 (12) | 34 (16) | 6 (5) |
| Mature | 18 (5) | 13 (6) | 5 (5) |
| T, nonspecified | 5 (1) | 4 (2) | 1 (1) |
| Cytogenetics (%) | |||
| Normal | 95/343 (28) | 60/214 (28) | 27/105 (26) |
| Abnormal | 157/343 (46) | 96/214 (45) | 50/105 (48) |
| Hyperdiploidy | 7 (2) | 7 (7) | 0 |
| Hypodiploidy | 10 (3) | 7 (7) | 2 (4) |
| t(v;11q23)/KMT2A | 24 (7) | 9 (10)§ | 13 (26)§ |
| t(1;19) | 12 (3) | 11 (12)§ | 1 (2)§ |
| t(12;21)/ETV6-RUNX1 | 2 (1) | 0 | 1 (2) |
| Other translocations | 18 (5) | 12 (13) | 4 (8) |
| del (9p) | 7 (2) | 7 (7) | 0 |
| del (12p) | 7 (2) | 2 (2) | 3 (6) |
| del (6q) | 4 (1) | 3 (3) | 1 (2) |
| Other deletions | 13 (4) | 8 (8) | 4 (8) |
| Complex (≥5 abnormalities) | 10 (3) | 6 (6) | 3 (6) |
| Other abnormalities | 43 (13) | 24 (25) | 18 (36) |
| Not evaluable | 91/343 (26) | 58/214 (27) | 28/105 (26) |
| Normal, <20 metaphases | 31 (9) | 21 (10) | 9 (8) |
| No growth | 60 (17) | 37 (17) | 19 (18) |
| Characteristic . | Whole series (n = 348) . | Chemotherapy (n = 218) . | Allo-HSCT (n = 106) . |
|---|---|---|---|
| Age, y | |||
| Median, range | 40 (15-60) | 39 (15-60) | 39 (16-60) |
| ≥30 y (%) | 262 (75) | 163 (75) | 76 (72) |
| Sex (%) | |||
| Male | 212 (61) | 128 (59) | 71 (67) |
| Female | 136 (39) | 90 (41) | 35 (33) |
| Extramedullary involvement | |||
| Mediastinum (%) | 51/334 (15) | 35/208 (17) | 15/103 (15) |
| CNS (%) | 38/331 (11) | 19/211 (9)† | 16/99 (16)† |
| Testicle (%) | 2/194 (1) | 1/119 (1) | 1/63 (2) |
| Other (%) | 21/328 (6)* | 12/207 (6) | 6/98 (6) |
| WBC count, ×109/L | |||
| Median, range | 13.5 (0.2-638) | 14.7 (0.2-564) | 13.2 (0.6-638) |
| WBC >30 × 109/L (%) | 138 (40) | 85 (39) | 43 (41) |
| WBC >100 × 109/L (%) | 64 (18) | 37 (17) | 25 (24) |
| Immunophenotype (%) | |||
| BCP | 241 (69) | 147 (67) | 74 (70) |
| Early pre-B | 39 (11) | 15 (7) | 19 (18) |
| Common | 158 (46) | 99 (45) | 48 (45) |
| Pre-B | 43 (12) | 33 (15) | 7 (7) |
| B, nonspecified | 1 (0.5) | 0 | 0 |
| T-ALL | 107 (31) | 71 (33) | 32 (30) |
| Early pre-T | 23 (7) | 5 (2)‡ | 17 (16)‡ |
| Pre-T | 19 (5.5) | 15 (7) | 3 (3) |
| Cortical | 42 (12) | 34 (16) | 6 (5) |
| Mature | 18 (5) | 13 (6) | 5 (5) |
| T, nonspecified | 5 (1) | 4 (2) | 1 (1) |
| Cytogenetics (%) | |||
| Normal | 95/343 (28) | 60/214 (28) | 27/105 (26) |
| Abnormal | 157/343 (46) | 96/214 (45) | 50/105 (48) |
| Hyperdiploidy | 7 (2) | 7 (7) | 0 |
| Hypodiploidy | 10 (3) | 7 (7) | 2 (4) |
| t(v;11q23)/KMT2A | 24 (7) | 9 (10)§ | 13 (26)§ |
| t(1;19) | 12 (3) | 11 (12)§ | 1 (2)§ |
| t(12;21)/ETV6-RUNX1 | 2 (1) | 0 | 1 (2) |
| Other translocations | 18 (5) | 12 (13) | 4 (8) |
| del (9p) | 7 (2) | 7 (7) | 0 |
| del (12p) | 7 (2) | 2 (2) | 3 (6) |
| del (6q) | 4 (1) | 3 (3) | 1 (2) |
| Other deletions | 13 (4) | 8 (8) | 4 (8) |
| Complex (≥5 abnormalities) | 10 (3) | 6 (6) | 3 (6) |
| Other abnormalities | 43 (13) | 24 (25) | 18 (36) |
| Not evaluable | 91/343 (26) | 58/214 (27) | 28/105 (26) |
| Normal, <20 metaphases | 31 (9) | 21 (10) | 9 (8) |
| No growth | 60 (17) | 37 (17) | 19 (18) |
Including pericardium and pleura (n = 4), pericardium (n = 1), pleura (n = 2), bone (n = 4), bone and pleura (n = 1), skin (n = 4), kidney (n = 2), kidney and pancreas (n = 1), ovary (n = 1), and muscle (n = 1).
P = .063.
Early pre–T- vs nonearly T-cell precursor: 5 vs 17; 66 vs 15 (P < .001).
t(v;11q23) vs t(1;19) vs other: 9 vs 13; 11 vs 1; 76 vs 36 (P = .007).